Apr. 13 at 4:27 AM
$SPY $CSGP $GFL $BNTX $MS
TOP 5 WEEKEND STORIES:
1) President Trump said on social media: "So, there you have it, the meeting went well, most points were agreed to, but the only point that really mattered, NUCLEAR, was not. Effective immediately, the United States Navy, the Finest in the World, will begin the process of BLOCKADING any and all Ships trying to enter, or leave, the Strait of Hormuz. At some point, we will reach an "ALL BEING ALLOWED TO GO IN, ALL BEING ALLOWED TO GO OUT" basis, but Iran has not allowed that to happen by merely saying, "There may be a mine out there somewhere," that nobody knows about but them. THIS IS WORLD EXTORTION, and Leaders of Countries, especially the United States of America, will never be extorted. I have also instructed our Navy to seek and interdict every vessel in International Waters that has paid a toll to Iran. No one who pays an illegal toll will have safe passage on the high seas.
2) Daniel Loeb's Third Point will not pursue a proxy fight against CoStar Group (CSGP), Svea Herbst-Bayliss of Reuters reports, citing sources familiar with the matter and a letter seen by Reuters. Third Point changed plans after it became clear that its plans to pressure CoStar into focusing more on the core business might not salvage the company, sources told Reuters. "We no longer believe that our original thesis holds true today and have disposed of our position in its entirety," Loeb wrote in a letter to investors seen by Reuters.
3) GFL Environmental (GFL) is planning to acquire Canada's Secure Waste Infrastructure (SECYF) in a transaction valued over
$4.3B including debt, with the deal expected to be structured with roughly 20% cash and 80% stock, Paula Sambo of Bloomberg reports, citing a person familiar with the matter. The proposed price is around C
$24.50 per share, the source added.
4) BioNTech (BNTX) announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan, BNT323 or DB-1303, in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment. This cohort is part of a global Phase 1/2a clinical trial investigating the HER2-targeted antibody-drug conjugate, ADC, candidate trastuzumab pamirtecan in multiple solid tumors. The data demonstrated clinically meaningful efficacy and a manageable safety profile for trastuzumab pamirtecan monotherapy across all HER2 immunohistochemistry expression levels.
5) Morgan Stanley (MS) analyst Yang Liu upgraded Bilibili to Overweight from Equal Weight with a price target of
$31, up from
$25. The firm sees "emerging value" in the shares with better game pipeline visibility for Bilibili. The company has AI adoption tailwinds and a more attractive valuation after the recent share pullback, the analyst tells investors in a research note. Morgan Stanley believes Bilibili's game business will enter new upcycle in the second half of 2026 backed by three new products.
